Naratriptan

DEA Class; Rx

Common Brand Names; Amerge

• Serotonin 5-HT-Receptor Agonists; 
• Antimigraine Agents

Hypersensitivity, including angioedema and anaphylaxis

Severe hepatic or renal impairment

Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders

Ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal’s angina)

History of stroke or TIA, or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke

Peripheral vascular disease

Ischemic bowel disease

Uncontrolled hypertension

Within 24 hours of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide)

• Dizziness
• Drowsiness
• Fatigue
• Paresthesias
• Pain/pressure sensation
• Nausea (1-5%)
• Throat/neck symptoms
• Myocardial infarction
• Coronary artery vasospasm in pts with CAD risk factors

Decrease dose with mild-moderate renal impairment

Anaphylaxis/anaphylactoid and hypersensitivity reactions, including angioedema reported (see Contraindications)

May cause dizziness, weakness, or drowsiness (infrequent)

Life-threatening disturbances of cardiac rhythm, including ventricular tachycardia and ventricular fibrillation leading to death, reported within a few hours following the administration of 5-HT1 agonists; discontinue therapy if these disturbances occur

Sensations of tightness, pain, and pressure in the chest, throat, neck, and jaw commonly occur after treatment and are usually non-cardiac in origin; however, perform a cardiac evaluation if these patients are at high cardiac risk

Therapy may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction (presenting with abdominal pain and bloody diarrhea), splenic infarction, and Raynaud’s syndrome; in patients who experience symptoms or signs suggestive of non-coronary vasospasm reaction following the use of any 5-HT1 agonist, rule out a vasospastic reaction before receiving additional doses

Reports of transient and permanent blindness and significant partial vision loss reported with the use of 5-HT1 agonists; since visual disorders may be part of a migraine attack, a causal relationship between these events and the use of 5-HT1 agonists have not been clearly established

Pregnancy: There are no adequate data on the developmental risk associated with use of naratriptan in pregnant women; several studies have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy

Lactation: There are no data on presence of naratriptan in human milk, effects of naratriptan on the breastfed infant, or effects of naratriptan on milk production; naratriptan is present in rat milk; the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for naratriptan and any potential adverse effects on the breastfed infant from naratriptan or from the underlying maternal condition

Naratriptan hydrochloride

tablet

• 1mg
• 2.5mg